Zelmac monotherapy shows promise in irritable bowel syndrome

The single treatment of Zelmac (tegaserod), a drug for the treatment of abdominal pain or discomfort and constipation in women with irritable bowel syndrome (IBS) being developed by Switzerland-based Novartis, could be a significant advance in treating this disabling condition, according to a local study.

In a recent satellite symposium hosted by the Korean Association for the Study of Intes...